News Headlines

  1. RoosterBio And MineBio Life Sciences Partner To Expand Access To Scalable, High Quality MSC And Exosome Bioprocessing Solutions In China 4/8/2026

    RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China's biopharmaceutical and advanced therapy community.

  2. BioOra And Octane Biotech Sign Letter Of Intent To Expand Cell Therapy Manufacturing Using The Cocoon Platform 4/7/2026

    BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.

  3. Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For RAD101 In The U.S. 4/7/2026

    Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, and Siemens Healthineers, today announced the signing of a supply agreement in which Siemens Healthineers will radiolabel and distribute RAD101 with Fluorine-18 (18F).

  4. NurExone Biologic's U.S. Subsidiary Exo-Top And Florida-Based BioXtek Sign Strategic LOI For Exosome Manufacturing And Commercialization 4/7/2026

    NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek Inc. (“BioXtek”) today announced that Exo-Top Inc., NurExone’s wholly owned U.S. subsidiary, (“Exo-Top” and together, with BioXtek, the “Parties”) has entered into a non-binding letter of intent (the “LOI”) with BioXtek, a Florida-based company, to explore a strategic partnership in the field of regenerative therapies for exosome manufacturing and commercialization.

  5. Pyramid Pharma Services Announces Drug Product Manufacturing Agreement For Phio Pharmaceuticals' Lead Oncology Candidate, PH-762 4/7/2026

    Pyramid Pharma Services, a U.S.-based contract development and manufacturing organization (CDMO), today announced that it has entered into a drug product manufacturing agreement with Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, to support the production of PH-762.

  6. Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities 4/7/2026

    Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025.

  7. Akari Therapeutics Announces Strategic Partnership With WuXi XDC To Advance Development Of Its Novel ADC Payload Targeting RNA Splicing 4/6/2026

    Akari Therapeutics, Plc, an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari’s novel PH1 payload.

  8. Oncotelic Therapeutics Announces Strategic Partnership With TechForce Robotics To Commercialize PDAOAI-Enhanced GMP Robotics Platform 4/2/2026

    Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced that it has entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform.

  9. Biodexa Announces Partnership With Syngene To Manufacture MTX240 GMP Clinical Trial Supplies 4/2/2026

    Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

  10. Thermo Fisher Scientific Introduces The Gibco CTS Compleo Fill and Finish System To Help Streamline Cell Therapy Manufacturing 4/2/2026

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing.